Report Description
Human Papilloma Virus Testing Market Outlook 2031
The global human papilloma virus testing market size was USD 930.32 Million in 2022 and is estimated to reach USD 2.23 Billion by 2031 register a considerable CAGR 10.24% during the forecast period, 2023–2031. The growth of the market is attributed to the increasing cases of cervical cancer world-wide.
The human papillomavirus (HPV) test helps to identify human papillomavirus present in the cells, which can further develop the abnormal cervical cells or cervical cancer, and genital warts. Routine usage of the HPV test under the age of 30 years is not recommended by specialists, as it is not very helpful. HPV is a type of infection majorly occurred through sexually transmitted and very common in young people.
However, HPV infections usually get easily recovered by itself within a year or two. As per a World Health Organization report, cervical cancer is the fourth most common cancer among women. The report stated that the number of the disease cases were around 570,000 in 2018, representing 6.6% of all female cancers and the mortality rate is 90% caused by cervical cancer in underdeveloped countries.
With the increasing cases of COVID-19 all over the world in 2020, patients’ visit for numerous elective medical procedures such as cancer screening and monitoring were found subsided. One key reason for the decreasing in cancer screening adoption was due to urgent shift of pharmaceutical companies to prioritize more on essential requirements and tackle the COVID-19 pandemic.
Human Papilloma Virus Testing Market Trends, Drivers, Restraints, and Opportunities
- High mortality rate due to HPV infection and rising cases especially in developing countries are key factors that are anticipated to boost the growth of the market in the coming years.
- Shortcoming of primary screening tests such as false or negative outcome, and less sensitivity for the detection of the virus is expected to upsurge the market.
- Increasing burden of cervical cancer globally which is more commonly found in females is another factor that fuel the market growth during the forecast period.
- Constantly changing in rules & regulations related to cervical cancer screening and HPV vaccination are major obstacles affecting the growth of the HPV testing market.
- Less-skilled healthcare workers operating the diagnostic devices is one of the primary reasons that can hamper the market growth.
- Growing awareness regarding the link between HPV and cervical cancer along with the increasing demand for accurate diagnostic testing is also projected to grow the market substantially.
Scope of The Human Papilloma Virus Testing Market Report
The report on the global human papilloma virus testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
Human Papilloma Virus Testing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2022
|
Historic Data
|
2016–2021
|
Forecast Period
|
2023–2031
|
Segmentation
|
Types (High-risk Human Papilloma Virus and Low-risk Human Papilloma Virus), Applications (Monoclonal & Polyclonal Antibodies, Immunoassays, Chromosome Analysis, Microarrays, Molecular Diagnostics, Flow Cytometry, Artificial Intelligence, Biosensors, and Microcomputers), and End-Users (Hospital & Clinics, Point of Care, and Diagnostic Centers)
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
Biomedical Diagnostics; Abbott; bioMerieux; CeMines, Inc; CanAG Diagnostics; Siemens Healthcare; Bio-Rad; Epigenomics; Fujirebio; Guided Therapeutics Inc; Ipsogen; Gen-Probe; J&J Diagnostics; Hologic; Polartechnics; Qiagen; Roche; Radient Pharmaceuticals; OncoLab; Sequenom; and Targeted Diagnostics & Therapeutics, Inc;
|
Human Papilloma Virus Testing Market Segment Insights
High-risk human papilloma virus segment is anticipated to hold a key market share
On the basis of types, the global human papillomavirus market is divided into high-risk human papilloma virus and low-risk human papilloma virus. The high-risk human papilloma virus segment is anticipated to hold a key market share during the forecast period owing to wide prevalence of high-risk disorders and availability of advanced diagnostic techniques for detecting the disorder.
Molecular diagnostic segment is expected to grow at a rapid pace
Based on applications, the market is segmented into monoclonal & polyclonal antibodies, immunoassays, chromosome analysis, microarrays, molecular diagnostics, flow cytometry, artificial intelligence, biosensors, and microcomputers. The molecular diagnostic segment is expected to grow at a rapid pace during the forecast period owing to the wide adoption of the diagnostic test for the detection of various types of high-risk HPV.
Molecular diagnostic tests are helpful for finding out the most appropriate diagnosis and treatments for patients. Others factors such as signal amplification, probe amplification, and target amplification in the detection and screening of HPV are expected to upsurge the market share of the segment.
Hospitals & clinics segment to register robust growth
On the basis of end-users, the global human papillomavirus market is segregated as hospital & clinics, point of care (PoC), and diagnostic centers. The hospitals & clinics segment is projected to register robust growth in the market during the forecast period as hospitals & clinics are well equipped with advanced diagnostic instruments, along with a wide availability of highly qualified medical personnel such as doctors, nurses, and technicians.
However, the PoC segment is anticipated to exhibit an impressive growth rate in the coming years due to increased demand for self-treatment and faster introduction of advanced home settings to enable simple access of patients.
North America is anticipated to constitute a key market share
In terms of regions, the global human papillomavirus testing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key share of the market during the forecast period.
The major factors attributing to the higher share market of the region are increasing cases of cancer and the initial stage of diagnosis and treatment awareness programs conducted by governments in the region. In addition to, governments led investments & grants have also positive impact on the growth of the HPV testing market in North America.
Meanwhile, the market of Asia Pacific is expected to grow at an impressive rate during the forecast period due to the rising prevalence of cervical cancer and sexually transmitted diseases such as HSV, and HIV, and cancroid. Advanced technology in screening assays, for determination of actual disease rather than the risk of predisposition to disease, are also projected to boost regional growth of market.
Segments
The global human papillomavirus testing market has been segmented on the basis of
Types
- High-risk Human Papilloma Virus
- Low-risk Human Papilloma Virus
Applications
- Monoclonal & Polyclonal Antibodies
- Immunoassays
- Chromosome Analysis
- Microarrays
- Molecular Diagnostics
- Flow Cytometry
- Artificial Intelligence
- Biosensors
- Microcomputers
End-Users
- Hospital & Clinics
- Point of Care
- Diagnostic Centers
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Biomedical Diagnostics
- Abbott
- bioMerieux
- CeMines, Inc.
- CanAG Diagnostics
- Siemens Healthcare
- Bio-Rad
- Epigenomics
- Fujirebio
- Guided Therapeutics Inc.
- Ipsogen
- Gen-Probe
- J&J Diagnostics
- Hologic
- Polartechnics
- Qiagen
- Roche
- Radient Pharmaceuticals
- OncoLab
- Sequenom
- Targeted Diagnostics & Therapeutics, Inc.
Competitive Landscape
Some of the major players competing in the market are Biomedical Diagnostics; Abbott; bioMerieux; CeMines, Inc; CanAG Diagnostics; Siemens Healthcare; Bio-Rad; Epigenomics; Fujirebio; Guided Therapeutics Inc; Ipsogen; Gen-Probe; J&J Diagnostics; Hologic; Polartechnics; Qiagen; Roche; Radient Pharmaceuticals; OncoLab; Sequenom; and Targeted Diagnostics & Therapeutics, Inc.
These key players are mainly focusing on organic & inorganic strategies such as merger & acquisition, approvals for products and licenses, agreements, partnerships, collaborations, and regional expansions to sustain their revenue share in the market.
Table Of Content
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Human Papilloma Virus Testing Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Human Papilloma Virus Testing Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Human Papilloma Virus Testing Market - Supply Chain
4.5. Global Human Papilloma Virus Testing Market Forecast
4.5.1. Human Papilloma Virus Testing Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Human Papilloma Virus Testing Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Human Papilloma Virus Testing Market Absolute $ Opportunity
5. Global Human Papilloma Virus Testing Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Human Papilloma Virus Testing Market Size and Volume Forecast by Types
5.3.1. High-risk Human Papilloma Virus
5.3.2.
Low-risk Human Papilloma Virus
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Human Papilloma Virus Testing Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Human Papilloma Virus Testing Market Size and Volume Forecast by Applications
6.3.1. Monoclonal & Polyclonal Antibodies
6.3.2.
Immunoassays
6.3.3.
Chromosome Analysis
6.3.4.
Microarrays
6.3.5.
Molecular Diagnostics
6.3.6.
Flow Cytometry
6.3.7.
Artificial Intelligence
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Human Papilloma Virus Testing Market Analysis and Forecast by End Users
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by End Users
7.2.2. Y-o-Y Growth Projections by End Users
7.3. Human Papilloma Virus Testing Market Size and Volume Forecast by End Users
7.3.1. Hospital & Clinics
7.3.2.
Point of Care
7.3.3.
Diagnostic Centers
7.4. Absolute $ Opportunity Assessment by End Users
7.5. Market Attractiveness/Growth Potential Analysis by End Users
8. Global Human Papilloma Virus Testing Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Human Papilloma Virus Testing Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Human Papilloma Virus Testing Demand Share Forecast, 2019-2026
9. North America Human Papilloma Virus Testing Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Human Papilloma Virus Testing Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Human Papilloma Virus Testing Market Size and Volume Forecast by Types
9.4.1. High-risk Human Papilloma Virus
9.4.2.
Low-risk Human Papilloma Virus
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. North America Human Papilloma Virus Testing Market Size and Volume Forecast by Applications
9.7.1. Monoclonal & Polyclonal Antibodies
9.7.2.
Immunoassays
9.7.3.
Chromosome Analysis
9.7.4.
Microarrays
9.7.5.
Molecular Diagnostics
9.7.6.
Flow Cytometry
9.7.7.
Artificial Intelligence
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. North America Human Papilloma Virus Testing Market Size and Volume Forecast by End Users
9.10.1. Hospital & Clinics
9.10.2.
Point of Care
9.10.3.
Diagnostic Centers
9.11. Basis Point Share (BPS) Analysis by End Users
9.12. Y-o-Y Growth Projections by End Users
9.13. Market Attractiveness/Growth Potential Analysis
9.13.1. By Country
9.13.2. By Product Type
9.13.3. By Application
9.14. North America Human Papilloma Virus Testing Demand Share Forecast, 2019-2026
10. Latin America Human Papilloma Virus Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Human Papilloma Virus Testing Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Human Papilloma Virus Testing Market Size and Volume Forecast by Types
10.4.1. High-risk Human Papilloma Virus
10.4.2.
Low-risk Human Papilloma Virus
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Latin America Human Papilloma Virus Testing Market Size and Volume Forecast by Applications
10.7.1. Monoclonal & Polyclonal Antibodies
10.7.2.
Immunoassays
10.7.3.
Chromosome Analysis
10.7.4.
Microarrays
10.7.5.
Molecular Diagnostics
10.7.6.
Flow Cytometry
10.7.7.
Artificial Intelligence
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Latin America Human Papilloma Virus Testing Market Size and Volume Forecast by End Users
10.10.1. Hospital & Clinics
10.10.2.
Point of Care
10.10.3.
Diagnostic Centers
10.11. Basis Point Share (BPS) Analysis by End Users
10.12. Y-o-Y Growth Projections by End Users
10.13. Market Attractiveness/Growth Potential Analysis
10.13.1. By Country
10.13.2. By Product Type
10.13.3. By Application
10.14. Latin America Human Papilloma Virus Testing Demand Share Forecast, 2019-2026
11. Europe Human Papilloma Virus Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Human Papilloma Virus Testing Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Human Papilloma Virus Testing Market Size and Volume Forecast by Types
11.4.1. High-risk Human Papilloma Virus
11.4.2.
Low-risk Human Papilloma Virus
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Europe Human Papilloma Virus Testing Market Size and Volume Forecast by Applications
11.7.1. Monoclonal & Polyclonal Antibodies
11.7.2.
Immunoassays
11.7.3.
Chromosome Analysis
11.7.4.
Microarrays
11.7.5.
Molecular Diagnostics
11.7.6.
Flow Cytometry
11.7.7.
Artificial Intelligence
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Europe Human Papilloma Virus Testing Market Size and Volume Forecast by End Users
11.10.1. Hospital & Clinics
11.10.2.
Point of Care
11.10.3.
Diagnostic Centers
11.11. Basis Point Share (BPS) Analysis by End Users
11.12. Y-o-Y Growth Projections by End Users
11.13. Market Attractiveness/Growth Potential Analysis
11.13.1. By Country
11.13.2. By Product Type
11.13.3. By Application
11.14. Europe Human Papilloma Virus Testing Demand Share Forecast, 2019-2026
12. Asia Pacific Human Papilloma Virus Testing Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Human Papilloma Virus Testing Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Human Papilloma Virus Testing Market Size and Volume Forecast by Types
12.4.1. High-risk Human Papilloma Virus
12.4.2.
Low-risk Human Papilloma Virus
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Asia Pacific Human Papilloma Virus Testing Market Size and Volume Forecast by Applications
12.7.1. Monoclonal & Polyclonal Antibodies
12.7.2.
Immunoassays
12.7.3.
Chromosome Analysis
12.7.4.
Microarrays
12.7.5.
Molecular Diagnostics
12.7.6.
Flow Cytometry
12.7.7.
Artificial Intelligence
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Asia Pacific Human Papilloma Virus Testing Market Size and Volume Forecast by End Users
12.10.1. Hospital & Clinics
12.10.2.
Point of Care
12.10.3.
Diagnostic Centers
12.11. Basis Point Share (BPS) Analysis by End Users
12.12. Y-o-Y Growth Projections by End Users
12.13. Market Attractiveness/Growth Potential Analysis
12.13.1. By Country
12.13.2. By Product Type
12.13.3. By Application
12.14. Asia Pacific Human Papilloma Virus Testing Demand Share Forecast, 2019-2026
13. Middle East & Africa Human Papilloma Virus Testing Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Middle East & Africa Average Pricing Analysis
13.2. Middle East & Africa Human Papilloma Virus Testing Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Human Papilloma Virus Testing Market Size and Volume Forecast by Types
13.4.1. High-risk Human Papilloma Virus
13.4.2.
Low-risk Human Papilloma Virus
13.5. Basis Point Share (BPS) Analysis by Types
13.6. Y-o-Y Growth Projections by Types
13.7. Middle East & Africa Human Papilloma Virus Testing Market Size and Volume Forecast by Applications
13.7.1. Monoclonal & Polyclonal Antibodies
13.7.2.
Immunoassays
13.7.3.
Chromosome Analysis
13.7.4.
Microarrays
13.7.5.
Molecular Diagnostics
13.7.6.
Flow Cytometry
13.7.7.
Artificial Intelligence
13.8. Basis Point Share (BPS) Analysis by Applications
13.9. Y-o-Y Growth Projections by Applications
13.10. Middle East & Africa Human Papilloma Virus Testing Market Size and Volume Forecast by End Users
13.10.1. Hospital & Clinics
13.10.2.
Point of Care
13.10.3.
Diagnostic Centers
13.11. Basis Point Share (BPS) Analysis by End Users
13.12. Y-o-Y Growth Projections by End Users
13.13. Market Attractiveness/Growth Potential Analysis
13.13.1. By Country
13.13.2. By Product Type
13.13.3. By Application
13.14. Middle East & Africa Human Papilloma Virus Testing Demand Share Forecast, 2019-2026
14. Competition Landscape
14.1. Global Human Papilloma Virus Testing Market: Market Share Analysis
14.2. Human Papilloma Virus Testing Distributors and Customers
14.3. Human Papilloma Virus Testing Market: Competitive Dashboard
14.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
14.4.1. Biomedical Diagnostics
14.4.2.
Abbott
14.4.3.
BioMerieux
14.4.4.
CeMines, Inc.
14.4.5.
CanAG Diagnostics
14.4.6.
Siemens Healthcare
14.4.7.
Bio-Rad
14.4.8.
Epigenomics&a